age limits on pneumo vaccinations
All infants should be given a primary series of PCV13, at ages 2, 4, and 6 months with a booster at age 12 to 15 months. Children who fall behind should be given catch-up vaccination through age 59 months, if otherwise healthy or, through age 71 months if they have certain underlying medical conditions. The type of pneumococcal vaccine you are given depends on your age and health. The two types are: pneumococcal conjugate vaccine (PCV) – this is used to vaccinate children under two years old as part of the NHS childhood vaccination programme. It's known by the brand name Prevenar 13. The Advisory Committee on Immunization Practices (ACIP) recommends that pneumococcal vaccine-nave people age 65 years and older should receive PCV13 first, followed by PPSV23 one year later. If the provider is unwilling to stock PCV13, then patients should be referred elsewhere to get PCV13 first. Routine Recommendations. for Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23) Risk Group. Administer PCV13 series to all children beginning. at age 2 months, followed by doses at 4 months, 6 months, and 12–15 months (booster dose). Administer 1-time dose to PCV13-naïve adults. at age 65 years, followed by a dose of PPSV23. PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). The type of pneumococcal vaccine you are given depends on your age and health. pneumococcal conjugate vaccine (PCV) – this is used to vaccinate children under two years old as part of the NHS childhood vaccination programme. It's known by the brand name Prevenar 13. Read the patient information leaflet for Prevenar 13. PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. People over age 65. As you age, your immune system doesn’t work as well as it once did. You’re more likely to have trouble fighting off a pneumonia infection. All adults over age 65 should get the vaccine. Those with weakened immune systems. For children. age 2 months. and older. 1 For PCV13 vaccination of healthy children, see “Recommen-. dations for Pneumococcal Vaccine Use in Children” at. www.immunize.org/catg.d/p2016.pdf. 2 Particularly cyanotic congenital heart disease and cardiac. failure in children; including congestive heart failure and. According to the ACIP recommendations published in September 2014, both pneumococcal conjugate vaccine (PCV13, Prevnar 13, Pfizer) and pneumococcal polysaccharide vaccine (PPSV23, Pneumovax, Merck) should be administered routinely in a series to all adults age 65 years and older.
65 years